zaurategrast cdp323  (MedChemExpress)

Journal: PLoS ONE

Article Title: Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study

doi: 10.1371/journal.pone.0058438

Figure Lengend Snippet: Percentage change from baseline in absolute lymphocyte counts at day 28 following treatment with CDP323 for 28 days (per protocol population).

Article Snippet: Small-molecule α 4 antagonists such as CDP323 (UCB Pharma, Brussels, Belgium, and Biogen Idec, Weston, MA, USA), a phenylalanine enamide mixed α 4 antagonist , have been considered potential alternatives to therapeutic antibodies because of their increased selectivity for specific α 4 -containing integrin complexes, their inhibition of different affinity states, and the increased patient convenience of oral dosing – .

Techniques: